{"filing":{"accession_number":"0001404644-26-000046","cik":"0001404644","ticker":"NGNE","company_name":"Neurogene Inc.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"ngne-20260629.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464426000046/ngne-20260629.htm"},"events":[{"id":14479,"run_id":12890,"accession_number":"0001404644-26-000046","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Neurogene disclosed positive clinical trial data from its Phase 1/2 trial of NGN-401 gene therapy for Rett syndrome, including 47 developmental milestones gained across 10 participants with durable effects through 30 months and no treatment-related serious adverse events.","company_name":"Neurogene Inc.","ticker":"NGNE","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":11933,"accession_number":"0001404644-26-000046","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Neurogene disclosed positive clinical trial data from its Phase 1/2 trial of NGN-401 gene therapy for Rett syndrome, including 47 developmental milestones gained across 10 participants with durable effects through 30 months and no treatment-related serious adverse events. While this is clinical progress on a lead program, it does not fit the specific earnings_release category (which typically applies to financial results) nor any other defined event type. The disclosure is material to investors assessing the company's pipeline and regulatory prospects, making operational_other the most appropriate classification for this clinical milestone announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T12:02:15.137503+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11934,"accession_number":"0001404644-26-000046","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Neurogene disclosed positive, updated clinical data from its Phase 1/2 trial of NGN-401 gene therapy for Rett syndrome, including 47 total developmental milestones gained across 10 participants with durable treatment effects through 30 months of follow-up and generally well-tolerated safety profile. This is a material clinical development milestone for a clinical-stage biotech company with a lead program in late-stage development (Embolden registrational trial), but does not fit the specific categories of earnings release, exec changes, M\u0026A, impairment, or other defined event types. The disclosure represents a significant operational/clinical progress update that would affect investor assessment of the company's pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T12:02:15.137503+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11933,"accession_number":"0001404644-26-000046","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Neurogene disclosed positive clinical trial data from its Phase 1/2 trial of NGN-401 gene therapy for Rett syndrome, including 47 developmental milestones gained across 10 participants with durable effects through 30 months and no treatment-related serious adverse events. While this is clinical progress on a lead program, it does not fit the specific earnings_release category (which typically applies to financial results) nor any other defined event type. The disclosure is material to investors assessing the company's pipeline and regulatory prospects, making operational_other the most appropriate classification for this clinical milestone announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T12:02:15.137503+00:00","company_name":"Neurogene Inc.","ticker":"NGNE","filing_date":"2026-06-29"},{"id":11934,"accession_number":"0001404644-26-000046","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Neurogene disclosed positive, updated clinical data from its Phase 1/2 trial of NGN-401 gene therapy for Rett syndrome, including 47 total developmental milestones gained across 10 participants with durable treatment effects through 30 months of follow-up and generally well-tolerated safety profile. This is a material clinical development milestone for a clinical-stage biotech company with a lead program in late-stage development (Embolden registrational trial), but does not fit the specific categories of earnings release, exec changes, M\u0026A, impairment, or other defined event types. The disclosure represents a significant operational/clinical progress update that would affect investor assessment of the company's pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T12:02:15.137503+00:00","company_name":"Neurogene Inc.","ticker":"NGNE","filing_date":"2026-06-29"}]}